Literature DB >> 28275413

The Impact of 2-(18) Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts.

Oana Stanca1, Anca Roxana Lupu1, Anca Ciobanu2, Irina Triantafyllidis1.   

Abstract

Positron emission tomography/computed tomography (PET/CT) is useful in staging of Hodgkin lymphoma (HL), for early response - adapted therapy and choosing an individualized therapy, and is useful in determination of disease extent in relapsed and refractory Hodgkin lymphoma. Interim PET using 2-(18) fluoro-2-deoxyglucose(FDG) and low dose CT performed in one scanning session (FDG-PET/ CT) helps to predict outcome in Hodgkin lymphoma and to asses therapeutic stratification.

Entities:  

Year:  2015        PMID： 28275413      PMCID： PMC5327805     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


  8 in total

Review 1.  PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.

Authors:  Eldad J Dann
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging.

Authors:  Gerard Moulin-Romsee; Elif Hindié; Xavier Cuenca; Pauline Brice; Didier Decaudin; Myriam Bénamor; Josette Brière; Marcela Anitei; Jean-Emmanuel Filmont; David Sibon; Eric de Kerviler; Jean-Luc Moretti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-04       Impact factor: 9.236

Review 3.  How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?

Authors:  Martin Hutchings
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

4.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Authors:  Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; Antony Ho; Josée Zijlstra; Zdenek Král; Michael Fuchs; Michael Hallek; Lothar Kanz; Hartmut Döhner; Bernd Dörken; Nicole Engel; Max Topp; Susanne Klutmann; Holger Amthauer; Andreas Bockisch; Regine Kluge; Clemens Kratochwil; Otmar Schober; Richard Greil; Reinhard Andreesen; Michael Kneba; Michael Pfreundschuh; Harald Stein; Hans Theodor Eich; Rolf-Peter Müller; Markus Dietlein; Peter Borchmann; Volker Diehl
Journal:  Lancet       Date:  2012-04-04       Impact factor: 79.321

Review 5.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

6.  Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

Authors:  Tarec Christoffer El-Galaly; Francesco d'Amore; Karen Juul Mylam; Peter de Nully Brown; Martin Bøgsted; Anne Bukh; Lena Specht; Annika Loft; Victor Iyer; Karin Hjorthaug; Anne Lerberg Nielsen; Ilse Christiansen; Charlotte Madsen; Hans-Erik Johnsen; Martin Hutchings
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

Review 7.  Hodgkin lymphoma.

Authors:  Paolo G Gobbi; Andrés J M Ferreri; Maurilio Ponzoni; Alessandro Levis
Journal:  Crit Rev Oncol Hematol       Date:  2012-08-04       Impact factor: 6.312

8.  Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Authors:  Diane Tseng; Leelanand P Rachakonda; Zheng Su; Ranjana Advani; Sandra Horning; Richard T Hoppe; Andrew Quon; Edward E Graves; Billy W Loo; Phuoc T Tran
Journal:  Radiat Oncol       Date:  2012-01-19       Impact factor: 3.481
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.